BRAF and acute myeloid leukemia: The IC50 levels of susceptible AML cells were in the range of physiologically relevant concentrations: Bimiralisib plasma levels were 2 μM in patients treated for solid tumors [32]; A-1331852 plasma levels were 2 μM in rat p.o. [33]; PTC-596 cmax ranged from 1 to 5 μM in patients with advanced tumors [34]; trametinib plasma levels were 20 nM in patients treated for BRAF melanoma [35].